• Ninlaro Combo Fails to Halt Progression of Newly Diagnosed Multiple Myeloma, Trial Data Show
  • Ide-cel Granted FDA Priority Review for Heavily-treated Multiple Myeloma
  • FDA Grants Fast Track Designation to ‘Off-the-shelf’ CAR T-cell Therapy
  • Investigational Myeloma Treatment KP1237 Wins FDA Orphan Drug Status
  • FDA Puts on Hold Phase 1 Cellectis Trial Testing CAR T-cell Therapy UCARTCS1A
  • LLS Highlights Its Support Programs During Blood Cancer Awareness Month
  • Melflufen Combo Earns FDA Priority Review for Triple-refractory Myeloma
  • Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma
  • Cilta-cel, CAR T-cell Treatment, Named Breakthrough Therapy in China
  • First-in-class Blenrep Approved by European Commission for Myeloma
  • FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma
  • Darzalex Faspro Combo Shows Benefits for Relapsed, Refractory Myeloma in Phase 3 Trial